Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer

Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be pr...

Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients

CHICAGO, June 1 /PRNewswire/ -- Researchers at the Barbara Ann Karmanos Cancer Institute in Detroit today presented findings that show immunotherapy with armed targeted T cells may improve the overall survival of women with metastatic breast cancer. (Logo: http://www.newscom.com/cgi-bin/p...

New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma

Gene Expression Profiling of Tumor is Correlated With Clinical Response CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by GlaxoSmithKline (GSK) today highlighted the potential of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) through results of three...

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

Data Reported at American Association for Cancer Research Annual Meeting SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced results from a new study showing enha...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

...ration (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CE...is: "Multikine: Cancer Immunotherapy; how to make immunotherapy for cancer work" . In the presentation, Dr. Talor will discuss Multikine's immunotherapy clinical program for cancer, the unique mechanism ...

USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic

...l Cancer Institute (NCI) for his breakthrough Interleukin-2 (IL-2) cytokine immunotherapy analog. This is the second RAID award Dr. Epstein has received from the N...or side effects that currently limit their application. IL-2 cytokine immunotherapy is used to treat metastatic melanoma and metastatic renal cell carcinoma, d...

Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells

...EC0225, a combination of two potent anticancer drugs; BMS493, a potent drug being developed in partnership with Bristol-Myers Squibb; EC17, a targeted immunotherapy agent; and EC0489, a targeted cancer drug. The Company also has multiple product candidates in pre-clinical stage development. ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

...h comparable results in humans. The lack of proinflammatory cytokine production in responses to the L.E.A.P.S. vaccines is especially important for an immunotherapy aimed at rheumatoid arthritis, since these cytokines cause much of the damage seen in rheumatoid arthritis patients, and has important implications fo...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... Neuroblastoma A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032 Lead investigator: A. L...

New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer

... --In a First, immunotherapy Works Against Neuroblastoma-- PHILADELPHIA, ...ndings online on May 14. Maris explained that immunotherapy for cancer involves triggering the body's immune s...ll transplantation). The patients who received the immunotherapy were 20 percent more likely than those in the stan...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

...hildren's Hospital Boston and Massachusetts General Hospital. About Hematopoietic Stem Cell Support Intensive chemotherapy, radiation, and/or immunotherapy are often used to treat patients with hematologic malignancies, such as leukemia and lymphoma, who have not been cured with conventional treatment. Th...

AlphaVax Announces Promising Results in Melanoma Studies

... tumor vaccine is currently ongoing at Duke University and a Her2 breast cancer clinical trial is planned for later this year. In addition to cancer immunotherapy programs, AlphaVax is developing vaccine products for herpes simplex virus, influenza, respiratory syncytial virus, HIV and a number of biodefense tar...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

...Compared to Placebo - - First Active Cellular immunotherapy for Cancer to Prolong Survival - - Company to...unmet medical need and create a new paradigm using immunotherapy for the treatment of men with advanced prostate ca...e the potential of our pipeline of active cellular immunotherapy product candidates that may help patients who are ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

...zation of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that c...

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

...omparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538. (3) Doehn C. immunotherapy of Prostate Cancer. Eur Uro . (2006);53-4:681-683. (4) American Cancer Society. How Many Men Get Prostate Cancer? http://www.cancer.org/docro...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

...zation of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon also is developing an orally-available small molecule that targets TRPM8 that c...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

...o-controlled trial will study the use of a standard dose of ToleroMune administered over a number of weeks. This is in marked contrast to most current immunotherapy treatments, which require carefully escalated weekly dosing over many months, followed by further monthly doses for several years, to reduce the risk ...

CEL-SCI Corporation Releases Letter to Shareholders

... For years most investors have shunned the cancer immunotherapy space because of the many failures of various comp...CEL-SCI have always tried to differentiate why our immunotherapy approach to treating cancer should be successful where other immunotherapy approaches have failed, the whole cancer...

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

...f PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. Those interested may ... identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is a...

New Hope to Beat Cancer

...0 from Anne's Hope Foundation. Milwaukee's own Northwestern Mutual Foundation has made its largest health care donation of $750,000 to Aurora's immunotherapy program, which has oversight of the Y-TIL Trial. Other contributors include A. Elser, Jr., William Schuett, Sr., Stella Jones and Sherwood and Libby T...

BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine

...induced up to 20-fold higher T-cell immune response as compared to the original version. Furthermore, it proved to be efficacious in additional tumour immunotherapy models in HER2 transgenic mice. The immunological situation regarding HER2 in those mice strongly resembles the situation in humans. Based on t...

Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival

...progression (recurrence) of 6.9 months (Stupp, et. al., N Engl J Med, 352:987, 2005, n = 573). As noted above, DCVax(R)-Brain is a personalized immunotherapy designed to stimulate a patient's own immune system to fight cancer. DCVax(R)-Brain is made up of the patient's own "dendritic cells," the master cell...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

...ja, MD, Clinica Ematologica DIRM AOUD, Udine, Italy This multicenter phase III study is the first to prospectively determine that adding the immunotherapy drug rituximab to dexamethasone (a steroid that is a standard therapy for ITP) is safe and effective in adult patients with previously untreated idiop...

Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer

... "We believe that anti-PD-1 antibodies could represent the next stage in immunotherapy with a promising mechanism of action and potential for marked synergy with ...ctivity in cancer. We look forward to the further development of this novel immunotherapy in cancer and, in a separate clinical trial, hepatitis C." In May ...

PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

...rovide the company with additional expert resources and technologies, and will facilitate rapid development of the product." Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers ...

Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium

...her evidence of the promise of our active cellular immunotherapy platform which also includes PROVENGE(R) (sipuleuc...er clinical development plans for NEUVENGE and our immunotherapy pipeline after that time." About NEUVENGE NEUV...ing and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune...

Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial

...nd efficacy of the investigational active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with metastatic ...d in our previous trials). About Active Cellular immunotherapy with PROVENGE PROVENGE may represent the first p...ing and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune...

Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial

...f PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. Those interested may ac... identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is al...

ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases

...ers. By using tumor-specific peptides, IVT's depot vaccines induce a potent cellular response that destroys 100% of the tumors, indicating a promising immunotherapy for cancer. About IVT ImmunoVaccine Technologies Inc., winner of Canada's Top 10 Life Sciences Companies, is a private, clinical-stage, vaccine de...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

... period of time in patients with advanced kidney cancer that progressed despite treatment with standard therapies," said Bernard Escudier, MD, Head of immunotherapy and Innovative Therapy Unit, Gustave-Roussy Institute, Paris, France. "Based on these findings, I believe RAD001 should become part of the treatment p...

Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax(R)-Brain

...urvival in GBM patients. As noted above, DCVax(R)-Brain is a personalized immunotherapy designed to stimulate a patient's own immune system to fight cancer. DCVax(... Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, witho...

Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber

...single centre, phase I study to assess, subsequent to allergen challenge in an allergen exposition chamber, the efficacy and time course of sublingual immunotherapy (SLIT) administered as 300IR allergen-based tablets once daily to 86 adults suffering from grass pollen rhinoconjunctivitis. The main objectives of th...

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105

...," said Howard H. Pien, President and CEO of Medarex. "We believe that our fully human anti-PD-1 and anti-PD-L1 antibodies represent the next stage in immunotherapy beyond the anti-CTLA-4 antibodies. We look forward to exploring the potential of MDX-1105 as a possible new treatment option for patients with cancer ...

Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD

...y Baxter International as a potential anti-amyloid immunotherapy for Alzheimer's. It contains a broad spectrum of a... Institutes of Health, that will test whether IVIg immunotherapy provides long-term benefits and has a disease-modi...t. Additional studies may be required." Phase II immunotherapy Trial with LY2062430 in Mild to Moderate Alzheimer...

Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October

...E is the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. Sho...etastatic prostate cancer. About Active Cellular immunotherapy with PROVENGE PROVENGE may represent the first p...ing and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune...